Table 3.
Treatment group | Prestudy | Pre-allocation | Last tolerated | % reduction from allocation |
---|---|---|---|---|
Placebo | 1681 (670) | 1079 (557) | 727 (743) | 30% |
Montelukast | 1588 (646) | 976 (553) | 526 (716) | 47%* |
P=0.046 compared with placebo.
Treatment group | Prestudy | Pre-allocation | Last tolerated | % reduction from allocation |
---|---|---|---|---|
Placebo | 1681 (670) | 1079 (557) | 727 (743) | 30% |
Montelukast | 1588 (646) | 976 (553) | 526 (716) | 47%* |
P=0.046 compared with placebo.